source
- Roivant's brepocitinib cuts steroid use in non-infectious uveitis in Phase 3 trialsRoivant Sciences and its subsidiary Priovant reported that their TYK2/JAK inhibitor brepocitinib met all primary and secondary endpoints in two identical Phase 3 studies (Clarity‑1 and Clarity‑2) i…
- US patients skip half of new high-cost drugs as prices surge past $250KA new report from the Institute for Clinical and Economic Review and West Health finds that only about one-third of patients prescribed newly launched medicines actually fill them within 30 days, w…